Ono Pharmaceutical Co Ltd 2015 IR
The report highlights Ono Pharmaceutical's financial and non-financial performance for the fiscal year ended March 31, 2015. Key achievements include the launch of Opdivo, the world's first approved anti-PD-1 antibody for unresectable melanoma in Japan, and the establishment of subsidiaries in South Korea and Taiwan. The company continued to focus on its 'Compound-Orient' drug discovery approach and open innovation. On the environmental front, the company worked toward its mid-term target of reducing CO2 emissions by 23% by FY2020 compared to FY2005, while maintaining zero waste emissions at its production and research sites.
Company: Ono Pharmaceutical Co Ltd
Sector: Health Care
Country: Japan
Year: 2015
Type: IR
Pages: 122
Ono Pharmaceutical Co Ltd
Corporate Report
The report highlights Ono Pharmaceutical's financial and non-financial performance for the fiscal year ended March 31, 2015. Key achievements include the launch of Opdivo, the world's first approved anti-PD-1 antibody for unresectable melanoma in Japan, and the establishment of subsidiaries in South Korea and Taiwan. The company continued to focus on its 'Compound-Orient' drug discovery approach and open innovation. On the environmental front, the company worked toward its mid-term target of reducing CO2 emissions by 23% by FY2020 compared to FY2005, while maintaining zero waste emissions at its production and research sites.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2015
Reporting Period
Apr 1, 2014 - Mar 31, 2015
Fiscal Year
2014
Published
Aug 1, 2015
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Energy Consumption
Water Consumption
Total Waste
Employees